Full Text Journal Articles by
Author Andrea Matucci

Advertisement

Find full text journal articles






Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.

Alessio Mazzoni, Lorenzo Salvati, Laura Maggi, Manuela Capone, Anna Vanni, Michele Spinicci, Jessica Mencarini, Roberto Caporale, Benedetta Peruzzi, Alberto Antonelli, Michele Trotta, Lorenzo Zammarchi, Luca Ciani, Leonardo Gori, Chiara Lazzeri, Andrea Matucci, Alessandra Vultaggio, Oliviero Rossi, Fabio Almerigogna, Paola Parronchi, Paolo Fontanari, Federico Lavorini, Adriano Peris, Gian Maria Rossolini, Alessandro Bartoloni, Sergio Romagnani, Francesco Liotta, Francesco Annunziato, Lorenzo Cosmi,

BACKGROUND:Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Anti-viral immune response is crucial to achieve pathogen clearance, however in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, ... Read more >>

J. Clin. Invest. (The Journal of clinical investigation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Immunogenicity - unwanted immune responses to biological drugs - can we predict them?

Matucci Andrea, Nencini Francesca, Vivarelli Emanuele, Bormioli Susanna, Maggi Enrico, Vultaggio Alessandra,

INTRODUCTION:. Biological agents (BAs) target molecules involved in disease mechanisms and have modified the natural history of several immune-mediated disorders. All BAs are immunogenic, resulting in the formation of antidrug antibodies (ADAs), which can neutralize drug activity leading to loss of response and potential relapse, or serious adverse events such ... Read more >>

Expert Rev Clin Pharmacol (Expert review of clinical pharmacology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype.

Riccardo Scarpa, Federica Pulvirenti, Antonio Pecoraro, Alessandra Vultaggio, Carolina Marasco, Roberto Ria, Sara Altinier, Nicolò Compagno, Davide Firinu, Mario Plebani, Marco De Carli, Andrea Matucci, Fabrizio Vianello, Angelo Vacca, Giuseppe Spadaro, Isabella Quinti, Carlo Agostini, Cinzia Milito, Francesco Cinetto,

We report on an observational, multicenter study of 345 adult CVID patients, designed to assess the diagnostic value and the clinical association of serum free light chain (sFLC) pattern in Common Variable Immunodeficiency disorders (CVID). Sixty CVID patients were tested twice in order to assess intraindividual variability of sFLC. As ... Read more >>

Front Immunol (Frontiers in immunology)
[2020, 11:319]

Cited: 0 times

View full text PDF listing >>



Systemic hypereosinophilic syndromes: when autoimmunity is Th2 mediated.

Andrea Matucci, Francesca Nencini, Enrico Maggi, Alessandra Vultaggio,

PURPOSE OF REVIEW:Clinical conditions associated with hypereosinophilia represent a field of particular interest, taking into account the epidemiological impact of the different primary and secondary forms. In addition to a classical Th1 response, also Th2 cells can be involved in the pathogenesis of autoimmune diseases, among them eosinophilic forms such ... Read more >>

Curr Opin Allergy Clin Immunol (Current opinion in allergy and clinical immunology)
[2020, 20(2):175-180]

Cited: 0 times

View full text PDF listing >>



Biologicals in atopic disease in pregnancy: an EAACI position paper.

Birgit Pfaller, Juan José Yepes-Nuñez, Ioana Agache, Cezmi A Akdis, Mohammad Alsalamah, Sevim Bavbek, Apostolos Bossios, Onur Boyman, Adam Chaker, Susan Chan, Alexia Chatzipetrou, George du Toit, Marek Jutel, Paula Kauppi, Antonios Kolios, Carmen Li, Andrea Matucci, Alanna Marson, Sarah Bendien, Oscar Palomares, Barbara Rogala, Zsolt Szepfalusi, Eva Untersmayr, Alessandra Vultaggio, Thomas Eiwegger,

Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. Although atopic diseases are among the most common diseases in the reproductive age, investigations, and information ... Read more >>

Allergy (Allergy)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reaction.

Alessandra Vultaggio, Francesca Nencini, Susanna Bormioli, Laura Dies, Emanuele Vivarelli, Enrico Maggi, Andrea Matucci,

J Allergy Clin Immunol Pract (The journal of allergy and clinical immunology. In practice)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.

Andrea Matucci, Enrico Maggi, Alessandra Vultaggio,

Bronchial asthma is a chronic inflammatory disease characterized, in a percentage of patients, as an eosinophilic inflammation of the airways. Eosinophils are recognized as a proinflammatory granulocyte playing a major role in the T2-high phenotype, which includes severe eosinophilic asthma. Eosinophilic asthma represents the majority of the phenotypic variants clinically ... Read more >>

Respir Med (Respiratory medicine)
[2019, 160:105819]

Cited: 0 times

View full text PDF listing >>



Hypersensitivity reactions to biologics used in rheumatology.

Andrea Matucci, Francesca Nencini, Enrico Maggi, Alessandra Vultaggio,

Introduction: Biological agents (BAs) target disease mechanisms and have modified the natural history of several immune-mediated disorders. All BAs are immunogenic, resulting in the formation of antidrug antibodies (ADAs), which can neutralize drug activity leading to loss of response and potential relapse. In addition, ADAs can also cause serious adverse ... Read more >>

Expert Rev Clin Immunol (Expert review of clinical immunology)
[2019, 15(12):1263-1271]

Cited: 0 times

View full text PDF listing >>



Concomitant bilastine and montelukast as additive therapy for seasonal allergic rhinoconjunctivits and mild-to-moderate asthma. The SKY study.

Federico Lavorini, Andrea Matucci, Oliviero Rossi, Massimo Pistolesi, ,

Allergy (Allergy)
[2020, 75(3):675-677]

Cited: 0 times

View full text PDF listing >>



Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study.

Clementina Canessa, Vera Gallo, Claudio Pignata, Antonino Trizzino, Simona Graziani, Baldassarre Martire, Viviana Moschese, Valentina Palladino, Giorgio Maria Boggia, Andrea Matucci, Antonio Pecoraro, Giuseppe Spadaro, Alessandra Vultaggio, Chiara Azzari,

Background: Subcutaneous immunoglobulin G (SCIG) may be a better option than intravenous immunoglobulin G (IVIG) for patients with primary immunodeficiencies (PID) due to reduced systemic and serious adverse reactions and easier administration. The Infusione Bimensile di Immunoglobuline Sottocute (IBIS) study investigated the effects of Hizentra®, a 20%-concentrated SCIG, administered biweekly ... Read more >>

Pediatr Allergy Immunol Pulmonol (Pediatric allergy, immunology, and pulmonology)
[2019, 32(2):70-75]

Cited: 0 times

View full text PDF listing >>



Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient.

Susanna Bormioli, Andrea Matucci, Laura Dies, Francesca Nencini, Francesca Grosso, Enrico Maggi, Alessandra Vultaggio,

Background:Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term side effects with conventional treatment options can be a significant clinical problem. ... Read more >>

Clin Mol Allergy (Clinical and molecular allergy : CMA)
[2019, 17:5]

Cited: 0 times

View full text PDF listing >>



Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies.

Cinzia Milito, Federica Pulvirenti, Francesco Cinetto, Vassilios Lougaris, Annarosa Soresina, Antonio Pecoraro, Alessandra Vultaggio, Maria Carrabba, Giuseppe Lassandro, Alessandro Plebani, Giuseppe Spadaro, Andrea Matucci, Giovanna Fabio, Rosa Maria Dellepiane, Baldassarre Martire, Carlo Agostini, Damiano Abeni, Stefano Tabolli, Isabella Quinti,

BACKGROUND:Lacking protective antibodies, patients with primary antibody deficiencies (PADs) experience frequent respiratory tract infections, leading to chronic pulmonary damage. Macrolide prophylaxis has proved effective in patients with chronic respiratory diseases. OBJECTIVE:We aimed to test the efficacy and safety of orally administered low-dose azithromycin prophylaxis in patients with PADs. METHODS:We designed ... Read more >>

J. Allergy Clin. Immunol. (The Journal of allergy and clinical immunology)
[2019, 144(2):584-593.e7]

Cited: 0 times

View full text PDF listing >>



Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.

Laura Maggi, Beatrice Rossettini, Gianni Montaini, Andrea Matucci, Alessandra Vultaggio, Alessio Mazzoni, Boaz Palterer, Paola Parronchi, Enrico Maggi, Francesco Liotta, Francesco Annunziato, Lorenzo Cosmi,

Even if omalizumab is broadly used in the treatment of severe, allergic asthma, the immunological effects in long-term treated patients have not been fully elucidated. To this aim, a cohort of 15 allergic asthmatic patients treated with omalizumab for at least three years was compared with 12 allergic asthma patients ... Read more >>

Eur. J. Immunol. (European journal of immunology)
[2018, 48(12):2005-2014]

Cited: 2 times

View full text PDF listing >>



Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy.

Raffaella Viti, Andrea Marcellusi, Alessandro Capone, Andrea Matucci, Alessandra Vultaggio, Claudio Pignata, Giuseppe Spadaro, Angelo Vacca, Carolina Marasco, Carlo Agostini, Francesco Saverio Mennini,

BACKGROUND:In Italy, there is scarce evidence on the epidemiological and economic burden induced by primary antibody deficiencies. OBJECTIVE:The aim of this study was to elaborate the available epidemiological and cost data in order to estimate the annual expenditure induced by the management of patients affected by the common variable immunodeficiency ... Read more >>

Clin Drug Investig (Clinical drug investigation)
[2018, 38(10):955-965]

Cited: 1 time

View full text PDF listing >>



The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review.

Andrea Matucci, Alessandra Vultaggio, Romano Danesi,

BACKGROUND:Monoclonal antibodies (mAbs) approved for use as add-on therapy in patients with severe asthma target the underlying pathogenesis of asthma. MAIN BODY:Omalizumab binds immunoglobulin E (IgE), thereby inhibiting its interaction with the high-affinity IgE receptor and reducing the quantity of free IgE available to trigger the allergic cascade. Anti-interleukin (IL)-5 ... Read more >>

Respir. Res. (Respiratory research)
[2018, 19(1):154]

Cited: 2 times

View full text PDF listing >>



The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment.

Andrea Matucci, Francesca Nencini, Oliviero Rossi, Sara Pratesi, Paola Parronchi, Enrico Maggi, Alessandra Vultaggio,

J Allergy Clin Immunol Pract (The journal of allergy and clinical immunology. In practice)
[2019, 7(1):339-340]

Cited: 0 times

View full text PDF listing >>



Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).

Alessandra Vultaggio, Chiara Azzari, Silvia Ricci, Baldassarre Martire, Valentina Palladino, Vera Gallo, Antonio Pecoraro, Claudio Pignata, Giuseppe Spadaro, Simona Graziani, Viviana Moschese, Antonino Trizzino, Giorgio Maria Boggia, Andrea Matucci,

Immunoglobulin G (IgG) replacement therapy is a standard treatment for patients with primary immunodeficiency diseases (PIDs). Hizentra®, a 20% human subcutaneous IgG (SCIG), is approved for biweekly administration for PIDs. The aim of the multicenter IBIS study was to prospectively investigate the efficacy of biweekly Hizentra® compared with previous IVIG ... Read more >>

J. Clin. Immunol. (Journal of clinical immunology)
[2018, 38(5):602-609]

Cited: 1 time

View full text PDF listing >>



Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

Andrea Matucci, Alessandra Vultaggio, Enrico Maggi, Ismail Kasujee,

Bronchial asthma (BA) is a chronic inflammatory disease with a marked heterogeneity in pathophysiology and etiology. The heterogeneity of BA may be related to the inducing mechanism(s) (allergic vs non-allergic), the histopathological background (eosinophilic vs non-eosinophilic), and the clinical manifestations, particularly in terms of severity and frequency of exacerbations. Asthma ... Read more >>

Respir. Res. (Respiratory research)
[2018, 19(1):113]

Cited: 6 times

View full text PDF listing >>



Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.

Andrea Matucci, Francesco Liotta, Emanuele Vivarelli, Laura Dies, Francesco Annunziato, Marie Pierre Piccinni, Francesca Nencini, Sara Pratesi, Enrico Maggi, Alessandra Vultaggio,

Gleich's syndrome (GS) is characterized by recurrent episodes of angioedema, increase in body weight, fever, hypereosinophilia, and elevated serum IgM. The exact etiology remains unclear. Currently, the only treatment strategy is the administration of high dose of steroids during the acute phases. We report the case of a 37-year-old man ... Read more >>

Front Immunol (Frontiers in immunology)
[2018, 9:1198]

Cited: 1 time

View full text PDF listing >>



The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.

Francesca Nencini, Alessandra Vultaggio, Sara Pratesi, Daniele Cammelli, Monica Milla, Ginevra Fiori, Siro Bagnoli, Francesca Prignano, Sergio Romagnani, Enrico Maggi, Andrea Matucci,

BACKGROUND:Hypersensitivity reactions (HRs) and loss of response (LOR) to infliximab (IFX) are related to drug immunogenicity characterized by antidrug antibodies (ADAs). OBJECTIVE:To analyze the timing of ADA appearance and its relationship with drug levels and clinical outcomes in IFX-treated patients with different diseases. METHODS:Samples were longitudinally collected before each infusion ... Read more >>

J Allergy Clin Immunol Pract (The journal of allergy and clinical immunology. In practice)
[2018, 6(6):2065-2072.e2]

Cited: 0 times

View full text PDF listing >>



Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.

Gianfranco Vitiello, Carolina Orsi Battaglini, Giulia Carli, Anna Radice, Andrea Matucci, Alessandra Vultaggio, Catia Olianti, Paola Parronchi, Enrico Maggi, Daniele Cammelli,

This study aims to evaluate (1) the efficacy and safety of tocilizumab (TCZ) as a steroid-sparing agent in patients with giant cell arteritis (GCA) and (2) the usefulness of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the follow-up and to detect disease activity. We retrospectively evaluated 12 patients with GCA treated ... Read more >>

Angiology (Angiology)
[2018, 69(9):763-769]

Cited: 2 times

View full text PDF listing >>



T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis.

Sara Pratesi, Francesca Nencini, Francesca Grosso, Laura Dies, Susanna Bormioli, Daniele Cammelli, Enrico Maggi, Andrea Matucci, Alessandra Vultaggio, ,

This study aimed to evaluate the proportion of infliximab (IFX)-exposed patients exhibiting cellular response to the drug in a longitudinal way and to establish whether it is predictive for anti-drug antibodies (ADA) development. Seventeen patients suffering from immuno-mediated disorders were enrolled. Blood was sampled at baseline and before each of ... Read more >>

Front Immunol (Frontiers in immunology)
[2018, 9:3113]

Cited: 0 times

View full text PDF listing >>



Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42].

Giuseppe Spadaro, Alessandra Vultaggio, Alberto Bosi, Dietmar Reichert, Jan Janssen, Donatella Lamacchia, Liliana Nappi, Antonio Pecoraro, Cinzia Milito, Andrea Ferraro, Andrea Matucci, Francesca Bacchiarri, Valentina Carrai, Azra Hibbeler, Elisabet Speckman, Chiara Guarnieri, Serena Bongiovanni, Isabella Quinti,

Int. Immunopharmacol. (International immunopharmacology)
[2018, 57:201]

Cited: 0 times

View full text PDF listing >>



IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients.

Alessandra Vultaggio, Francesca Nencini, Sara Pratesi, Daniele Cammelli, Maria Totaro, Sergio Romagnani, Enrico Maggi, Andrea Matucci, ,

Infliximab (IFX) is a chimeric mAb that can lead to the appearance of anti-drug Abs. Recent research has identified the presence of circulating IFX-specific T cells in treated patients. The aim of the study was to analyze the functional characteristics of IFX-specific T cells, in particular their capability to produce ... Read more >>

J. Immunol. (Journal of immunology (Baltimore, Md. : 1950))
[2017, 199(4):1283-1289]

Cited: 2 times

View full text PDF listing >>



Targeted therapy in severe asthma today: focus on immunoglobulin E.

Girolamo Pelaia, Giorgio Walter Canonica, Andrea Matucci, Rossella Paolini, Massimo Triggiani, Pierluigi Paggiaro,

Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard "one size fits all" approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide ... Read more >>

Drug Des Devel Ther (Drug design, development and therapy)
[2017, 11:1979-1987]

Cited: 10 times

View full text PDF listing >>



Advertisement

Disclaimer
0.9448 s